Michael Petrosky, MD, of the Allegheny Health Network, discusses how monoclonal antibodies will help in the prevention of respiratory syncytial virus (RSV) in infants.
Michael Petrosky, MD, of the Allegheny Health Network, spoke about the potential impact of monoclonal antibodies on the prevention and treatment of respiratory syncytial virus (RSV) in infants.
Transcript
Do you see treatment for RSV becoming more proactive with the new monoclonal antibody?
I definitely agree with that, and living in the world of pediatrics, that's our big thing is prevention. That's why we're big on the vaccine schedules. That's why we have to see children every so often make sure they're growing and developing well, to just sort of help prevent serious issues or if we can catch things earlier, we know outcomes are definitely better. It'll definitely be more preventative. What's nice is we're able to get more kids vaccinated, get kids more immune to RSV, at least for the short amount of time, and with pretty much less of a hassle. If you only have to come in once to get the job done, as opposed to 5 times, it's definitely helpful. So it's going to get kids covered for longer periods of time and get more kids covered.
Will these monoclonal antibodies become as commonplace as the flu vaccine?
I think at this point, if this is what we have, then yes, it'll definitely help because we know this is really the only thing we have to cover to protect infants against RSV. Going back to your earlier question, where you mentioned other injections, immunizations come along. So there are actually vaccines for RSV, but it's for the older population, those 60 and older. And that's more that active immunization. I think, until we can get a good active vaccination program for infants, monoclonal antibodies will help. We know last year was pretty rough with RSV; it came a whole lot earlier than expected [and] lasted longer. So we know the more we can prevent [1 child] from getting it, that's 1 less child that can then pass it on to someone else. So we know, until we get something better, these monoclonal antibodies are going to be the best that we have to help prevent RSV in infants.
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Kansas City Tuberculosis Outbreak Highlights Ongoing Public Health Challenge
February 11th 2025In an interview with The American Journal of Managed Care, Michael A. Bernstein, MD, stressed the need for effective communication and proactive screening to curb the recent tuberculosis (TB) outbreak.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Addressing the Bidirectional Impact of Schizophrenia and Substance Use Disorders
February 8th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.
Read More
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More